PRESSMEDDELANDE
IDOGEN AB

Org nr. 556756–8521
Datum: 21 September 2022

Idogen has received approval from the regional ethics committee to conduct a clinical phase I/IIa study within the IDO 8 program for hemophilia at Oslo University Hospital

Idogen AB (publ) announces today that the company has received approval from the Norwegian REK (Regionale komiteer for medicinsk og helsefaglig forskningetikk) in Oslo to conduct the clinical phase I/IIa study of their drug candidate within the IDO 8 program for patients suffering from hemophilia who have developed antibodies against their life-saving factor VIII treatment. The approval means that study activities can begin at the clinic and that the first patient can be enrolled in the study within short.

Idogen has now received approval from the ethics committee in Oslo to conduct the company's phase I/IIa study in hemophilia with the drug candidate, ItolDC-028. The study is conducted under the leadership of professor and senor physician Pål Andre Holme. Shortly, the first patient will be able to be enrolled, after which the first step in the treatment will be possible to be carried out.

"After intensive preparations and great commitment at our Norwegian trial center, we are now ready to start recruiting patients for the phase I/II study of our first drug candidate, ItolDC-028. The step into clinical phase is the most important milestone so far in the development of our unique cell therapy, to develop a product that can treat or prevent the development of antibodies against the important treatment with coagulation factor VIII (FVIII)", says Hanjing Xie, CMO of Idogen.

For further information, please contact:

Christina Herder, acting CEO, Idogen AB
Phone: +46 70 37 47 156
Email: christina.herder@idogen.com

Certified Advisor:

Vator Securities AB.

The information was submitted for publication, through the agency of the contact persons set out above, on 21 September, 2022,at 08:02 CET.

The English text is an unofficial translation of the original Swedish text. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.

Idogen's (Nasdaq First Growth Market: IDOGEN) unique technology platform enables the development of various tolerogenic cell therapies with the potential to restore the immune system's tolerance to counteract its attacks against, for example, biological drugs, transplanted organs or the body's own tissue. The company's most advanced program IDO 8 aims to treat hemophilia patients who have developed an unwanted immune response to their drug treatment. As previously announced, Idogen has received approval from the Swedish and Norwegian pharmaceutical authorities to conduct the first clinical phase I/IIa study with its drug candidate within the IDO 8 program in patients with severe bleeding disorders, so-called hemophiliaThe company's second development program, IDO T, aims to prevent rejection of transplanted kidneys. In an additional program, IDO AID, Idogen focuses on developing treatment for various autoimmune diseases. The treatment for all indications is based on the patient's own cells and is expected to have a favorable safety profile and long-term effect. The fact that a short treatment intervention has the potential to produce a very long-lasting effect is a major health economic benefit for both patients and care units. More information about Idogen is available via https://www.idogen.com